Palatin Technologies, Inc.

0KF3

US6960776010

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 10:06:10 2026-05-22 am EDT			5-day change	1st Jan Change
15.01 ^USD	-28.52%		+4.60%	-45.83%

May. 31	Palatin Technologies, Inc.(NasdaqCM:PTN) added to NASDAQ Composite Index	CI
May. 18	Palatin Technologies to Transfer Listing to Nasdaq	MT

Palatin Technologies, Inc.:

Published on 08/11/2025

Factset

PALATIN TECHNOLOGIES, INC.

-28.52%

A reverse split is applied today to 's stock price.

Latest news about Palatin Technologies, Inc.

May. 31	Palatin Technologies, Inc.(NasdaqCM:PTN) added to NASDAQ Composite Index	CI
May. 18	Palatin Technologies to Transfer Listing to Nasdaq	MT
May. 13	Palatin Technologies, Inc., Q3 2026 Earnings Call, May 13, 2026
May. 13	Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
Feb. 17	Palatin Technologies, Inc., H1 2026 Earnings Call, Feb 17, 2026
Feb. 17	Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
Jan. 05	Certain Warrants of Palatin Technologies, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026.	CI
Jan. 05	Certain Stock Options of Palatin Technologies, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026.	CI
Jan. 05	973,291 Common Stock of Palatin Technologies, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026.	CI
Dec. 21	Palatin Technologies, Inc.(NYSEAM:PTN) added to S&P TMI Index	CI
Nov. 14	Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
Nov. 13	Palatin Technologies, Inc., Q1 2026 Earnings Call, Nov 13, 2025
Nov. 13	Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln	RE
25-09-23	Palatin Technologies, Inc. Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-09-22	Palatin Technologies, Inc. Auditor Raises 'Going Concern' Doubt	CI

Chart Palatin Technologies, Inc.

Duration

Period

0KF3: Dynamic Chart

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. It develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. It also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.

Employees

Sector

Biotechnology & Medical Research

More about the company